Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LYM019
MIFTS: 46

Lymphosarcoma

Categories: Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lymphosarcoma

About this section

MalaCards integrated aliases for Lymphosarcoma:

Name: Lymphosarcoma 20 54
Lymphoma, Diffuse 70
Lymphoma 70

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 70 C0024299 C3714542
Sources

Summaries for Lymphosarcoma

About this section
MalaCards based summary : Lymphosarcoma, also known as lymphoma, diffuse, is related to reticulum cell sarcoma and lymphoma, non-hodgkin, familial. An important gene associated with Lymphosarcoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and Chromatin Regulation / Acetylation. The drugs Idarubicin and Ferrous succinate have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and bone, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 73 T-lymphoblastic leukemia/lymphoma (WHO 2008), previously labeled precursor T-lymphoblastic... more...

Sources

Related Diseases for Lymphosarcoma

About this section

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 reticulum cell sarcoma 30.9 TNFRSF8 PTPRC
2 lymphoma, non-hodgkin, familial 29.9 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
3 follicular lymphoma 29.9 IGH BCL6 BCL2
4 alpha chain disease 29.8 CD22 BCL6
5 reticulosarcoma 29.5 TNFRSF8 PTPRC IGH BCL6 BCL2
6 lymphoblastic lymphoma 29.5 TNFRSF8 PTPRC BCL6
7 lymphoproliferative syndrome 29.2 TNFRSF8 PTPRC BCL6
8 leukemia, chronic myeloid 29.2 PTPRC G6PD DNMT1 BCL2
9 hodgkin's lymphoma, lymphocytic-histiocytic predominance 29.1 TNFRSF8 PTPRC BCL6
10 diffuse large b-cell lymphoma 29.1 TNFRSF8 PTPRC BCL6 BCL2
11 burkitt lymphoma 29.0 TNFRSF8 DNMT1 BCL6 BCL2
12 leukemia, chronic lymphocytic 28.9 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
13 peripheral t-cell lymphoma 28.9 TNFRSF8 PTPRC DNMT3A BCL6
14 mantle cell lymphoma 28.8 PTPRC IGH BCL6 BCL2
15 t-cell lymphoblastic leukemia/lymphoma 28.6 TNFRSF8 PTPRC NR3C1 ERVW-1 BCL2
16 leukemia, acute lymphoblastic 28.5 TNFRSF8 PTPRC NR3C1 IGH CD22 BCL6
17 leukemia, acute myeloid 28.5 TNFRSF8 PTPRC DNMT3A DNMT1 CD22 BCL6
18 b-cell lymphoma 28.2 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
19 sarcoma 10.4
20 spindle cell sarcoma 10.4
21 acute leukemia 10.4
22 trimethoprim allergy 10.3 GSR G6PD
23 meningococcal infection 10.3 GSR G6PD
24 eye lymphoma 10.2 CD22 BCL6
25 leukemia 10.2
26 parotitis 10.2 H6PD G6PD
27 soft palate cancer 10.2 CD22 BCL6
28 epiglottis neoplasm 10.1 PTPRC BCL6
29 heart lymphoma 10.1 PTPRC BCL6
30 hemolytic anemia 10.1
31 glucosephosphate dehydrogenase deficiency 10.1 H6PD GSR G6PD
32 plasmablastic lymphoma 10.1 PTPRC BCL6
33 hypereosinophilic syndrome 10.1
34 posttransplant acute limbic encephalitis 10.1
35 nodal marginal zone b-cell lymphoma 10.1 BCL6 BCL2
36 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.1 BCL6 BCL2
37 intussusception 10.1
38 mycosis fungoides 10.1
39 splenomegaly 10.1
40 intravascular large b-cell lymphoma 10.0 BCL6 BCL2
41 ataxia and polyneuropathy, adult-onset 10.0
42 yemenite deaf-blind hypopigmentation syndrome 10.0
43 lymphoma 10.0
44 uveitis 10.0
45 lymphopenia 10.0
46 peritonitis 10.0
47 exophthalmos 10.0
48 neuropathy, hereditary sensory, type ie 10.0 DNMT3A DNMT1
49 testicular torsion 10.0 GSR BCL2
50 human herpesvirus 8 10.0 BCL6 BCL2

Graphical network of the top 20 diseases related to Lymphosarcoma:



Diseases related to Lymphosarcoma
Sources

Symptoms & Phenotypes for Lymphosarcoma

About this section

GenomeRNAi Phenotypes related to Lymphosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 CD22 CTSL DNMT3A NR3C1 PTPRC

MGI Mouse Phenotypes related to Lymphosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.81 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD
2 endocrine/exocrine gland MP:0005379 9.56 BCL2 BCL6 DNMT3A H6PD NR3C1 PTPRC
3 hematopoietic system MP:0005397 9.32 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD
Sources

Drugs & Therapeutics for Lymphosarcoma

About this section

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 824)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Idarubicin Approved Phase 4 58957-92-9 42890
2
Ferrous succinate Approved Phase 4 10030-90-7
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
12
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-56-5 148211
13
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
14
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
15
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
17
Etoposide Approved Phase 4 33419-42-0 36462
18
Teniposide Approved Phase 4 29767-20-2 34698
19
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
20
Mercaptopurine Approved Phase 4 50-44-2 667490
21
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
22
Daunorubicin Approved Phase 4 20830-81-3 30323
23
Nitric Oxide Approved Phase 4 10102-43-9 145068
24
Infliximab Approved Phase 4 170277-31-3
25
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
26
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
27
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
28
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
29
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
30
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
31
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
32
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
33
Prilocaine Approved Phase 4 721-50-6 4906
34
tannic acid Approved Phase 4 1401-55-4
35
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
36
Epirubicin Approved Phase 4 56420-45-2 41867
37
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
38
Methoxsalen Approved Phase 4 298-81-7 4114
39
Zidovudine Approved Phase 4 30516-87-1 35370
40
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
41
Ledipasvir Approved Phase 4 1256388-51-8 67505836
42
Ribavirin Approved Phase 4 36791-04-5 37542
43
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
44
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
45
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
46
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
47
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
48
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
49
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
50
Fotemustine Investigational Phase 4 92118-27-9

Interventional clinical trials:

(show top 50) (show all 6707)
# Name Status NCT ID Phase Drugs
1 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
2 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
4 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
5 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
6 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
7 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
8 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Unknown status NCT03150602 Phase 4 Pralatrexate
9 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
10 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unknown status NCT03631862 Phase 4 Apatinib;CHOP Regimen
11 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
12 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
13 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Unknown status NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
14 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
15 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
16 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
17 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
18 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
19 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
20 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
21 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
22 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
23 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
24 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
25 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
26 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
27 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
28 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
29 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
30 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
31 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
32 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
33 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
34 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
35 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
36 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
37 AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
38 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
39 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
40 Assisted Oocyte Activation (AOA) in Recurrent Fertilization Failure Completed NCT04744753 Phase 4 Calcium Ionophore A23187
41 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
42 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
43 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
44 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
45 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
46 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
47 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
48 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
49 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
50 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen

Search NIH Clinical Center for Lymphosarcoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa
Sources

Genetic Tests for Lymphosarcoma

About this section
Sources

Anatomical Context for Lymphosarcoma

About this section

MalaCards organs/tissues related to Lymphosarcoma:

40
T Cells, Bone Marrow, Bone, Skin, Myeloid, Small Intestine, Liver
Sources

Publications for Lymphosarcoma

About this section

Articles related to Lymphosarcoma:

(show top 50) (show all 4277)
# Title Authors PMID Year
1
Suppression of metallothionein-I/II expression and its probable molecular mechanisms. 61 54
12426140 2002
2
[Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas]. 61 54
11494447 2001
3
Study on the anti-hepatocarcinoma effect and molecular mechanism of Prunella vulgaris total flavonoids. 61
33675913 2021
4
Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020. 61
33733992 2021
5
Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. 61
30999803 2021
6
Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. 61
33528622 2021
7
Proteomic profiling of milk small extracellular vesicles from bovine leukemia virus-infected cattle. 61
33536533 2021
8
PTEN Loss and Cyclin A2 Upregulation Define a PI3K/AKT Pathway Activation in Helicobacter pylori-induced MALT and DLBCL Gastric Lymphoma With Features of MALT. 61
32134755 2021
9
A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene - A Case Report and Literature Review. 61
33679144 2021
10
Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. 61
32995955 2020
11
Hematolymphoid Neoplasms Rarely Mimic Undifferentiated Pleomorphic Sarcoma of Soft Tissue. 61
32167380 2020
12
Data on proteomic analysis of milk extracellular vesicles from bovine leukemia virus-infected cattle. 61
33294510 2020
13
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. 61
31789821 2020
14
Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates. 61
32870521 2020
15
Antitumour Activity of the Ribonuclease Binase from Bacillus pumilus in the RLS40 Tumour Model Is Associated with the Reorganisation of the miRNA Network and Reversion of Cancer-Related Cascades to Normal Functioning. 61
33147876 2020
16
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. 61
32888407 2020
17
Phylogenetic Analysis of South African Bovine Leukaemia Virus (BLV) Isolates. 61
32824449 2020
18
Impact of bovine leukemia virus infection on beef cow longevity. 61
32593082 2020
19
Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma. 61
32755987 2020
20
Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG. 61
32757068 2020
21
CpG Site-Specific Regulation of Metallothionein-1 Gene Expression. 61
32824906 2020
22
Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma. 61
32647417 2020
23
Vitamin D levels in patients with non-Hodgkin lymphoma/diffuse large B-cell lymphoma, chronic lymphocytic leukemia and multiple myeloma. 61
32722995 2020
24
Diffuse large B cell lymphoma in a preceding IgG4-related disease with kidney restricted lambda light chain expression: case report and literature review. 61
32727411 2020
25
[Application of Antinuclear Antibody and Antinuclear Antibody Spectrum in Lymphoma Treatment]. 61
32552948 2020
26
Targeting Circulating SINEs and LINEs with DNase I Provides Metastases Inhibition in Experimental Tumor Models. 61
32146418 2020
27
Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. 61
32153241 2020
28
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. 61
32030731 2020
29
Update on the subcutaneous administration of rituximab in Canadian cancer centres. 61
32489254 2020
30
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. 61
32135128 2020
31
To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma). 61
32073552 2020
32
An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. 61
32228625 2020
33
Rare case of Richter's syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) - Case report and literature. 61
32208597 2020
34
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma. 61
32014922 2020
35
Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. 61
32457824 2020
36
Whole genome sequencing analysis of high confidence variants of B-cell lymphoma in Canis familiaris. 61
32857815 2020
37
Foliate Lymphoid Aggregates as Novel Forms of Serous Lymphocyte Entry Sites of Peritoneal B Cells and High-Grade B Cell Lymphomas. 61
31767783 2020
38
Primary pulmonary lymphoma manifesting as diffuse ground glass opacities: a case report and literature review. 61
32922618 2020
39
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. 61
31648953 2019
40
Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma. 61
31840115 2019
41
Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-ÙŽAnalysis. 61
31759344 2019
42
Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives. 61
30993718 2019
43
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. 61
30045683 2019
44
Detection and Identification of Enzootic Bovine Leukosis (EBL) in Calves in Iran. 61
31592598 2019
45
The Unsolved Puzzle of c-Rel in B Cell Lymphoma. 61
31277480 2019
46
Prevalence and clinical significance of koala retrovirus in two South Australian koala (Phascolarctos cinereus) populations. 61
31162024 2019
47
Surveillance scanning in lymphoma. 61
31437139 2019
48
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. 61
30795996 2019
49
A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma-diffuse large B-cell lymphoma (DOBL study): Study protocol and design. 61
32935480 2019
50
Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation. 61
30909988 2019
Sources

Variations for Lymphosarcoma

About this section
Sources

Expression for Lymphosarcoma

About this section
Search GEO for disease gene expression data for Lymphosarcoma.
Sources

Pathways for Lymphosarcoma

About this section

Pathways related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Immune response Fc epsilon RI pathway 23
Show member pathways
 11.99 PTPRC IGH CD22 BCL6
2
Chromatin Regulation / Acetylation 4
11.66 SMARCA4 NR3C1 DNMT3A DNMT1
3
Direct p53 effectors 1
11.62 SMARCA4 BCL6 BCL2
4
Sulfation Biotransformation Reaction 1
10.51 GSR G6PD
5
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
10.27 SMARCA4 DNMT3A DNMT1 BCL2
Sources

GO Terms for Lymphosarcoma

About this section

Cellular components related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.62 DNMT1 BCL6

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.92 SMARCA4 NR3C1 DNMT3A DNMT1 BCL6
2 regulation of gene expression GO:0010468 9.78 PTPRC DNMT3A DNMT1 BCL2
3 chromatin organization GO:0006325 9.76 SMARCA4 NR3C1 DNMT3A DNMT1
4 negative regulation of cell growth GO:0030308 9.67 SMARCA4 BCL6 BCL2
5 response to gamma radiation GO:0010332 9.55 PTPRC BCL2
6 DNA methylation GO:0006306 9.54 DNMT3A DNMT1
7 B cell differentiation GO:0030183 9.54 PTPRC BCL6 BCL2
8 negative regulation of reactive oxygen species metabolic process GO:2000378 9.51 G6PD BCL2
9 pentose-phosphate shunt GO:0006098 9.43 H6PD G6PD
10 NADP metabolic process GO:0006739 9.4 H6PD G6PD
11 DNA methylation involved in embryo development GO:0043045 9.32 DNMT3A DNMT1
12 C-5 methylation of cytosine GO:0090116 9.26 DNMT3A DNMT1
13 pentose-phosphate shunt, oxidative branch GO:0009051 9.16 H6PD G6PD
14 positive regulation of B cell proliferation GO:0030890 9.13 PTPRC BCL6 BCL2
15 DNA methylation on cytosine GO:0032776 8.62 DNMT3A DNMT1

Molecular functions related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 9.33 H6PD GSR G6PD
2 oxidoreductase activity, acting on CH-OH group of donors GO:0016614 9.32 H6PD G6PD
3 DNA-methyltransferase activity GO:0009008 9.26 DNMT3A DNMT1
4 DNA (cytosine-5-)-methyltransferase activity GO:0003886 8.96 DNMT3A DNMT1
5 glucose-6-phosphate dehydrogenase activity GO:0004345 8.62 H6PD G6PD
Sources

Sources for Lymphosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....